Diabetes decisions — 2025

The Board denied increased evaluations for diabetic peripheral neuropathy, diabetes mellitus, type II, and a separate compensable evaluation for dry eye.

The Board denied the appeal to restore service connection for diabetes mellitus type II, finding clear and unmistakable error in the original grant of service connection due to a lack of qualifying service near the DMZ.

The Board denied service connection for type II diabetes mellitus, erectile dysfunction, hypertension, and bleeding of the eyes as there is no evidence that these conditions are related to the Veteran's military service.

The Board granted an 80 percent disability rating for seizure disorder, a 30 percent rating for left eye atrophy and blindness, and a TDIU due to the seizure disorder. The discontinuation of the 100 percent disability rating for Rosai-Dorfman disease was upheld.

The Board remands the claims for service connection for coronary artery disease and type II diabetes due to inadequate medical opinions regarding toxic exposures, including jet fuel and cleaning solvents.

The appeal was dismissed due to procedural defects, and the Board denied a higher evaluation for diabetes mellitus, type II.

The Board denied increased ratings for hypertension and hemorrhoids but granted service connection for diabetes mellitus as secondary to hemorrhoids.

The Board granted service connection for diabetes mellitus, hypertension, and kidney disease, while denying service connection for a low back disability, hip pain, and a neurobehavioral disorder. The claim for a gastrointestinal disability was remanded for further consideration.

The Board denied service connection for a digestive disorder, bilateral foot pain, bilateral hearing loss, diabetes, degenerative arthritis (claimed as lower back pain), and migraines. However, tinnitus was granted.

The Board granted service connection for coronary artery disease and diabetes mellitus, type II, due to presumed exposure to herbicides at Fort McClellan. The claims for gastroesophageal reflux disease, hypertension, sinusitis, diverticulitis, and fibromyalgia were remanded for further development.

The Board denied service connection for asthma, COPD, CAD (claimed as heart disease), DMII, and a kidney disorder based on the evidence not persuasively supporting an in-service incurrence or relationship to service.

The Board denied service connection for diabetes mellitus, type II, sinusitis, hypertension, and chronic kidney disease with hypertensive renal disease. The Board also denied a compensable disability rating for allergic rhinitis.

The Board granted service connection for diabetes mellitus type II as secondary to the Veteran's service-connected lumbosacral strain, resolving reasonable doubt in favor of the Veteran.

The Veteran's service-connected disabilities have precluded him from obtaining or engaging in substantially gainful employment since August 29, 2016.

The Board remands the claims for further development and readjudication by the Regional Office due to a duty to assist error regarding the verification of in-service exposure to herbicide agents or other toxic exposure risk activities.

The Board granted service connection for diabetes mellitus type II, hepatitis B, a liver condition (hepatic steatosis and cirrhosis) secondary to service-connected hepatitis B, hypertension, prostate cancer, voiding dysfunction as secondary to service-connected prostate cancer, and erectile dysfunction as secondary to service-connected prostate cancer. The claim for anemia was remanded.

The Board denied the veteran's claims for higher ratings for hypertension, arteriosclerotic heart disease, and diabetes mellitus.

The Board denied higher initial ratings for diabetes mellitus, type II; right lower extremity diabetic peripheral neuropathy; and general anxiety disorder. The issues of service connection for left and right eye disabilities and entitlement to a total disability rating based on individual unemployability due to service-connected disabilities were remanded.

The Board granted 40 percent ratings for right and left lower extremity peripheral neuropathy, a 30 percent rating for left upper extremity peripheral neuropathy, and denied an increased rating in excess of 20 percent for diabetes mellitus type II.

The Board granted service connection for diabetes mellitus type II, coronary artery disease, Parkinson's disease, and neuropathy, as due to herbicide exposure or secondary to a service-connected condition.